New research where traditional Chinese medicine was found to safely and effectively treat patients with persistent atopic dermatitis — or eczema, as it’s commonly known — could lead more physicians to prescribe complementary and alternative medicine (CAM) to treat the allergic condition.
In the study presented at the 2009 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), researchers at Mount Sinai Hospital in New York analyzed 14 patients with persistent atopic dermatitis who received traditional Chinese medicine at Ming Qi Natural Health Center in Manhattan between August 2006 and May 2008. The treatments consisted of Erka Shizheng Herbal Tea, a bath additive, creams and acupuncture.
The study authors utilized two measures: the SCORAD index to gauge atopic dermatitis severity and the Dermatology Life Quality Index (DLQI) to calculate impairment to life quality.
Baseline median scores for SCORAD and DLQI were 89 and 17, respectively. After a median of eight months treatment, the median scores fell to 11 for SCORAD and 1 for DLQI.
In all but one patient, SCORAD measures decreased between 60 to 90% after 3.3 months of treatment. More than 50% improvement in DLQI scores was documented in all but one patient after 2.4 months of treatment.
Patients also reported a reduction in the use of steroids, antibiotics and antihistamines within three months of being treated with traditional Chinese medicine. There were no abnormalities of liver and kidney function observed.
©2009 Community News Group
By submitting this comment, you agree to the following terms:
You agree that you, and not BrooklynDaily.com or its affiliates, are fully responsible for the content that you post. You agree not to post any abusive, obscene, vulgar, slanderous, hateful, threatening or sexually-oriented material or any material that may violate applicable law; doing so may lead to the removal of your post and to your being permanently banned from posting to the site. You grant to BrooklynDaily.com the royalty-free, irrevocable, perpetual and fully sublicensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part world-wide and to incorporate it in other works in any form, media or technology now known or later developed.